Co-administration of Nanowired DL-3-n-Butylphthalide (DL-NBP) Together with Mesenchymal Stem Cells, Monoclonal Antibodies to Alpha Synuclein and TDP-43 (TAR DNA-Binding Protein 43) Enhance Superior Neuroprotection in Parkinson's Disease Following Concussive Head Injury
- PMID: 37480460
- DOI: 10.1007/978-3-031-32997-5_3
Co-administration of Nanowired DL-3-n-Butylphthalide (DL-NBP) Together with Mesenchymal Stem Cells, Monoclonal Antibodies to Alpha Synuclein and TDP-43 (TAR DNA-Binding Protein 43) Enhance Superior Neuroprotection in Parkinson's Disease Following Concussive Head Injury
Abstract
dl-3-n-butylphthalide (dl-NBP) is one of the potent antioxidant compounds that induces profound neuroprotection in stroke and traumatic brain injury. Our previous studies show that dl-NBP reduces brain pathology in Parkinson's disease (PD) following its nanowired delivery together with mesenchymal stem cells (MSCs) exacerbated by concussive head injury (CHI). CHI alone elevates alpha synuclein (ASNC) in brain or cerebrospinal fluid (CSF) associated with elevated TAR DNA-binding protein 43 (TDP-43). TDP-43 protein is also responsible for the pathologies of PD. Thus, it is likely that exacerbation of brain pathology in PD following brain injury may be thwarted using nanowired delivery of monoclonal antibodies (mAb) to ASNC and/or TDP-43. In this review, the co-administration of dl-NBP with MSCs and mAb to ASNC and/or TDP-43 using nanowired delivery in PD and CHI-induced brain pathology is discussed based on our own investigations. Our observations show that co-administration of TiO2 nanowired dl-NBP with MSCs and mAb to ASNC with TDP-43 induced superior neuroprotection in CHI induced exacerbation of brain pathology in PD, not reported earlier.
Keywords: Alpha synuclein; Brain pathology; Dopamine; Mesenchymal stem cells; Nanowired delivery; Neuroprotection; Parkinson’s disease; Phosphorylated tau; TDP-43.
© 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Similar articles
-
Co-administration of TiO2-nanowired dl-3-n-butylphthalide (dl-NBP) and mesenchymal stem cells enhanced neuroprotection in Parkinson's disease exacerbated by concussive head injury.Prog Brain Res. 2020;258:101-155. doi: 10.1016/bs.pbr.2020.09.011. Epub 2020 Nov 9. Prog Brain Res. 2020. PMID: 33223034
-
Mild traumatic brain injury exacerbates Parkinson's disease induced hemeoxygenase-2 expression and brain pathology: Neuroprotective effects of co-administration of TiO2 nanowired mesenchymal stem cells and cerebrolysin.Prog Brain Res. 2020;258:157-231. doi: 10.1016/bs.pbr.2020.09.010. Epub 2020 Nov 9. Prog Brain Res. 2020. PMID: 33223035 Review.
-
Nanowired delivery of dl-3-n-butylphthalide with antibodies to alpha synuclein potentiated neuroprotection in Parkinson's disease with emotional stress.Int Rev Neurobiol. 2023;171:47-82. doi: 10.1016/bs.irn.2023.06.005. Epub 2023 Jul 20. Int Rev Neurobiol. 2023. PMID: 37783563
-
Neuroprotective Effects of Nanowired Delivery of Cerebrolysin with Mesenchymal Stem Cells and Monoclonal Antibodies to Neuronal Nitric Oxide Synthase in Brain Pathology Following Alzheimer's Disease Exacerbated by Concussive Head Injury.Adv Neurobiol. 2023;32:139-192. doi: 10.1007/978-3-031-32997-5_4. Adv Neurobiol. 2023. PMID: 37480461 Review.
-
Nanowired delivery of DL-3-n-butylphthalide induces superior neuroprotection in concussive head injury.Prog Brain Res. 2019;245:89-118. doi: 10.1016/bs.pbr.2019.03.008. Epub 2019 Apr 2. Prog Brain Res. 2019. PMID: 30961873 Review.
Cited by
-
Elucidating molecular pathogenesis and developing targeted therapeutic interventions for cerebrovascular endothelial cell-mediated vascular dementia.Front Aging Neurosci. 2025 Jul 16;17:1623050. doi: 10.3389/fnagi.2025.1623050. eCollection 2025. Front Aging Neurosci. 2025. PMID: 40741047 Free PMC article. Review.
References
-
- The Lancet Neurology. Parkinson’s disease needs an urgent public health response. Lancet Neurol. 2022;21(9):759. https://doi.org/10.1016/S1474-4422(22)00312-X .
-
- Crotty GF, Keavney JL, Alcalay RN, Marek K, Marshall GA, Rosas HD, Schwarzschild MA. Planning for prevention of Parkinson disease: now is the time. Neurology. 2022;99(7 Suppl 1):1–9. https://doi.org/10.1212/WNL.0000000000200789 . - DOI - PubMed
-
- Zhou X, Liu Z, Zhou X, Xiang Y, Zhou Z, Zhao Y, Pan H, Xu Q, Chen Y, Sun Q, Wu X, Tan H, Li B, Yuan K, Xie Y, Liao W, Hu S, Zhu J, Wu X, Li J, Wang C, Lei L, Tang J, Liu Y, Wu H, Huang W, Wang T, Xue Z, Wang P, Zhang Z, Xu P, Chen L, Wang Q, Wang X, Cheng O, Shen Y, Liu W, Ye M, You Y, Li J, Yan X, Guo J, Tang B, for Parkinson’s Disease & Movement Disorders Multicenter Database and Collaborative Network in China (PD-MDCNC). The Chinese Parkinson’s Disease Registry (CPDR): study design and baseline patient characteristics. Mov Disord. 2022;37(7):1335–45. https://doi.org/10.1002/mds.29037 . Epub 2022 May 3 - DOI - PubMed
-
- Bock MA, Tanner CM. The epidemiology of cognitive function in Parkinson’s disease. Prog Brain Res. 2022;269(1):3–37. https://doi.org/10.1016/bs.pbr.2022.01.004 . Epub 2022 Feb 4 - DOI - PubMed
-
- Ulivelli M, Bezzini D, Kundisova L, Grazi I, Battaglia MA, Nante N, Rossi S. Mortality of Parkinson’s disease in Italy from 1980 to 2015. Neurol Sci. 2022;43(6):3603–11. https://doi.org/10.1007/s10072-021-05854-3 . Epub 2022 Jan 30 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical